generation run 2026-05-14
64 min completedmodel pipeline-v5plan not recordedrun/725bd8e7…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
4 further caveats recorded as free text — readable on the working page
Reproduce
- inputs
- 38 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
26 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | Banisteriopsis caapi alkaloids pharmacology | 15 | 13 | All relevant to alkaloid profile, pharmacology, safety, and mechanisms of B. caapi |
| 2 | PubMed · absence | Banisteriopsis caapi ethnobotany ayahuasca history | 0 | — | — |
| 3 | PubMed · absence | ayahuasca adverse effects safety toxicity case report | 0 | — | — |
| 4 | PubChem | harmine | 1 | — | — |
| 5 | OpenAlex | Banisteriopsis caapi taxonomy botany | 10 | 2 | Davis & Anderson 2010 covers Malpighiaceae phylogeny; Schultes 1957 is foundational on B. caapi identity |
| 6 | PubMed | ayahuasca beta-carboline alkaloid concentration measurement analysis | 6 | — | — |
| 7 | ClinicalTrials.gov | ayahuasca Banisteriopsis caapi | 2 | — | — |
| 8 | PubChem | tetrahydroharmine | 1 | — | — |
| 9 | PubMed | harmine MAO monoamine oxidase inhibitor serotonin receptor mechanism | 2 | — | — |
| 10 | PubChem | harmaline | 1 | — | — |
| 11 | ClinicalTrials.gov | ayahuasca DMT harmine depression PTSD treatment | 1 | — | — |
| 12 | POWO (Kew Gardens) | — | 1 | — | — |
| 13 | PubMed | harmine harmaline tetrahydroharmine beta-carboline concentration ayahuasca brew preparation | 3 | 3 | Critical alkaloid quantification data |
| 14 | OpenAlex | harmine antidepressant neurogenesis hippocampal beta-carboline mechanism | 8 | 1 | Key mechanism paper for antidepressant effects via neurogenesis |
| 15 | OpenAlex | Banisteriopsis caapi phylogeny domestication cerrado Malpighiaceae | 1 | — | — |
| 16 | WebSearch + ICEERS | ayahuasca legal status United States DEA Schedule Europe Netherlands Peru Brazil regulation | 10 | — | — |
| 17 | OpenAlex | ayahuasca safety adverse events deaths serotonin syndrome drug interactions | 8 | — | — |
| 18 | PubMed | ayahuasca long-term users mental health personality psychopathology | 1 | 1 | — |
| 19 | PubMed | ayahuasca depression antidepressant clinical trial randomized | 10 | 4 | Key clinical efficacy papers for ayahuasca antidepressant effects |
| 20 | PubMed | Riba ayahuasca pharmacokinetics pharmacodynamics human volunteers | 6 | 6 | These are landmark clinical pharmacology studies of ayahuasca |
| 21 | OpenAlex | ayahuasca MAOI contraindications drug interactions serotonin toxicity safety | 8 | — | — |
| 22 | PubMed | ayahuasca neuroimaging fMRI brain activity default mode network | 3 | 2 | — |
| 23 | WebSearch | ayahuasca drug test detection urine DMT harmine immunoassay standard panel | 10 | — | — |
| 24 | PubMed | Riba 2015 DMT metabolism oral smoked urine disposition | 1 | — | — |
| 25 | PubMed | Pope 2019 harmala alkaloids urine drug screen forensic | 1 | — | — |
| 26 | PubMed+OpenAlex cross-reference | Banisteriopsis caapi key data synthesis | — | — | — |
162 claims by section — every cited sentence, checked against its source
safety66 · 6 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
In controlled clinical settings, a diastolic blood pressure increase of approximately 9 mmHg was observed at higher doses (0.85 mg dmt/kg), along with mild sympathomimetic effects including pupil dilation, prolactin elevation, and cortisol elevationpartially supported
Diastolic BP increased 9 mmHg at high dose. Doses 0.6 and 0.85 mg DMT/kg. pmid:12660312
In controlled clinical settings, a diastolic blood pressure increase of approximately 9 mmHg was observed at higher doses (0.85 mg dmt/kg), along with mild sympathomimetic effects including pupil dilation, prolactin elevation, and cortisol elevationpartially supported
Ayahuasca increased prolactin, cortisol; mild sympathomimetic effects; immunomodulatory effects on lymphocytes. Milder effects on pupil than amphetamine. jcp.0b013e31823607f6
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
No significant alteration in liver function tests (ALT, AST, bilirubin, creatinine, urea, LDH, alkaline phosphatase, GGT) was found in 22 chronic ayahuasca users consuming the preparation twice monthly for at least one year.supported
22 volunteers consuming ayahuasca twice monthly or more for ≥1 year. No significant alterations in liver function tests (ALT, AST, bilirubin, creatinine, etc.). Chronic ayahuasca use does not appear to affect hepatic function. 02791072.2018.1557355
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Long-term ritual users consuming ayahuasca at least twice monthly for years show no cognitive impairment and no pattern of addiction-related problemssupported
No evidence of psychological maladjustment, mental health deterioration or cognitive impairment. Users scored lower on all psychopathology measures, better performance on Stroop, WCST, and Letter-Number Sequencing tasks. journal.pone.0042421
Preserved or improved cognitive function — including enhanced working memory — has been confirmed in cross-sectional study of long-term users versus beginnerssupported
48 participants: 16 experienced users (>20 years), 16 beginners (<3 years), 16 controls. No cognitive decline in either user group. Experienced group showed higher working verbal and visuospatial memory scores than beginners. s00406-024-01817-9
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Severe cardiovascular disease: Mild diastolic blood pressure increase (~9 mmHg) and sympathomimetic activation documented at standard dosessupported
Diastolic BP increased 9 mmHg at high dose. Predominantly peripheral site of action for harmine. pmid:12660312
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
neuroscience26 · 8 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
From a double-blind placebo-controlled study (n=18, doses of 0.6 and 0.85 mg DMT/kg body weight):supported
Double-blind placebo-controlled trial with 18 volunteers. Doses 0.6 and 0.85 mg DMT/kg. pmid:12660312
A factorial dose-escalation study of buccal DMT (0–120 mg) combined with harmine (0–180 mg) reported peak DMT Cmax of 33 ng/mL and harmine Cmax of 49 ng/mL, with subjective effects lasting 4–5 hours and Tmax increasing with dose escalation for both compounds.supported
Peak DMT Cmax 33 ng/mL, harmine Cmax 49 ng/mL. T_max increased with dose escalation. Effects lasted 4-5h. j.biopha.2025.117908
Harmine is a potent, reversible mao-a inhibitor with Ki in the low nanomolar range — the primary pharmacological action of B. caapisupported
Harmine inhibits DMT metabolism via MAO-A. kfaf118
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
It also exhibits anti-inflammatory activity via COX inhibition, nitric oxide pathway suppression, and Nrf-2/antioxidant signaling activation, with reductions in IL-1β documented in preclinical models.supported
Harmaline 5 mg/kg reduces pain and inflammation in mice via COX and nitric oxide pathways, antioxidant Nrf-2 activation, IL-1beta reduction. s00210-025-04220-w
Harmine from B. caapi inhibits this enzyme, enabling DMT from admixture plants to reach systemic circulation and cross the blood-brain-barriersupported
DMT Cmax 12.14 and 17.44 ng/mL respectively. Predominantly peripheral site of action for harmine. pmid:12660312
Harmine from B. caapi inhibits this enzyme, enabling DMT from admixture plants to reach systemic circulation and cross the blood-brain-barriersupported
Harmine inhibits DMT metabolism via MAO-A. Simulation results show route of administration and harmine co-administration influence DMT exposure. kfaf118
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Harmine, THH, harmaline, and the harmine metabolite harmol all stimulate adult neurogenesis in vitro — promoting neural stem cell proliferation, migration, and differentiation in mouse brain neurospheres from both the subventricular zone and subgranular zonesupported
Harmine, tetrahydroharmine, and harmaline from B. caapi all stimulate adult neurogenesis in vitro; neural stem cell proliferation, migration, and differentiation in mouse brain neurospheres. s41598-017-05407-9
Systematic review of classical hallucinogen neuroimaging confirms acute excitation of frontolateral and frontomedial cortex, medial temporal lobe, and occipital cortex alongside DMN inhibitionsupported
Systematic review of 25 neuroimaging studies of serotonergic hallucinogens. Acute effects: excitation of frontolateral/frontomedial cortex, medial temporal lobe, occipital cortex; inhibition of DMN. j.neubiorev.2016.10.026
summary24 · 4 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
The 1996 Hoasca Project produced the first human plasma pharmacokinetic data, and a 2018 placebo-controlled trial demonstrated significant rapid antidepressant effects in treatment-resistant depressionsupported
First controlled trial of a psychedelic in treatment-resistant depression. NCT02914769. Supports safety and therapeutic value of ayahuasca for depression. s0033291718001356
Claim in summary — inconclusiveinconclusiveworking →
Harmine, the dominant alkaloid (mean 4.79 mg/g dried liana, RSD 170%), is a potent reversible MAO-A inhibitor at low nanomolar concentrationspartially supported
Harmine inhibits DMT metabolism via MAO-A. kfaf118
In ayahuasca preparations, this inhibition prevents gastrointestinal and hepatic deamination of DMT from the admixture plant, enabling oral bioavailability of an otherwise orally inactive tryptaminesupported
DMT Cmax 12.14 and 17.44 ng/mL respectively, Tmax ~1.5h. Predominantly peripheral site of action for harmine. pmid:12660312
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Long-term ritual users show no cognitive impairment, physical-dependence, or addiction-related problemssupported
No evidence of psychological maladjustment, mental health deterioration or cognitive impairment. Users scored lower on all psychopathology measures, better performance on Stroop, WCST, and Letter-Number Sequencing tasks. journal.pone.0042421
Claim in summary — inconclusiveinconclusiveworking →
preparations16 · 2 ok
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Dose: In controlled research settings, standardized ayahuasca has been administered at 0.6–0.85 mg DMT/kg body weight (encapsulated freeze-dried material)supported
Doses 0.6 and 0.85 mg DMT/kg. pmid:12660312
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Mild cardiovascular effects include diastolic blood pressure increase (~9 mmHg at higher doses) and mild pupil dilationpartially supported
Diastolic BP increased 9 mmHg at high dose. pmid:12660312
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
alkaloid-profile14 · 2 ok
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Validated analytical methods for these alkaloids include GC, HPLC with limit-of-quantification values of 0.3–1.0 ng/mL in plasma, and LC-MS/MSsupported
Developed analytical methodology for plasma quantification of DMT and beta-carboline alkaloids (harmine, harmaline, THH, harmol, harmalol). DMT LOQ 1.6 ng/mL, beta-carbolines 0.3-1.0 ng/mL. pmid:12361741
Wang and colleagues confirmed the dominant constituents and characterized their monoamine-oxidase-inhibitory and antioxidative activities.supported
Banisteriopsis caapi contains harmine, harmaline, tetrahydroharmine. MAO inhibitory and antioxidative constituents relevant to neurological disorders. j.jep.2010.02.013
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
history12 · 0 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →